Table 2.
Estimation of overall success rates by inverse-probability-of-treatment weighting*
| Counts |
Reweighted |
Estimated overall success rate |
||||||
|---|---|---|---|---|---|---|---|---|
| Rule | No. | S1 | S2 | F | S1 | S2 | F | P (95% CI) |
| d(CVD, KA/VE) | 14 | 4 | 5 | 5 | 2.2 | 5.9 | 5.9 | 0.58 (0.28 to 0.86) |
| d(CVD, TEC) | 10 | 4 | 1 | 5 | 1.5 | 1.4 | 7.1 | 0.29 (0.06 to 0.63) |
| d(CVD, TEE) | 10 | 4 | 0 | 6 | 1.5 | 0.0 | 8.5 | 0.15 (0.04 to 0.31) |
| d(KA/VE, CVD) | 14 | 7 | 0 | 7 | 3.5 | 0.0 | 10.5 | 0.25 (0.10 to 0.42) |
| d(KA/VE, TEC) | 15 | 7 | 0 | 8 | 3.8 | 0.0 | 11.2 | 0.25 (0.10 to 0.42) |
| d(KA/VE, TEE) | 13 | 7 | 0 | 6 | 3.2 | 0.0 | 9.8 | 0.25 (0.10 to 0.42) |
| d(TEC, CVD) | 19 | 14 | 1 | 4 | 8.9 | 2.0 | 8.1 | 0.57 (0.33 to 0.85) |
| d(TEC, KA/VE) | 18 | 14 | 0 | 4 | 8.4 | 0.0 | 9.6 | 0.47 (0.28 to 0.65) |
| d(TEC, TEE) | 21 | 14 | 0 | 7 | 9.8 | 0.0 | 11.2 | 0.47 (0.28 to 0.65) |
| d(TEE, CVD) | 14 | 10 | 1 | 3 | 5.8 | 2.0 | 6.1 | 0.56 (0.28 to 1.00) |
| d(TEE, KA/VE) | 14 | 10 | 0 | 4 | 5.8 | 0.0 | 8.2 | 0.42 (0.22 to 0.61) |
| d(TEE, TEC) | 16 | 10 | 1 | 5 | 6.7 | 1.6 | 7.8 | 0.51 (0.28 to 0.78) |
The number of subjects whose treatment history is compatible with a given dynamic rule and the number of overall failures (F) as well as successes on the first-line regimen (S1) and the salvage regimen (S2) for that rule are shown. In addition to the original counts, the table shows them reweighted by the inverse of the estimated probability of a given patient being assigned to his observed treatment history. The inverse-probability-of-treatment–weighted estimates of the overall success rates of the different dynamic rules along with 95% bootstrap confidence intervals (CIs) are also shown. The dynamic rule d(f, s) assigns a patient to the first-line regimen f until the treatment fails to produce a positive response, at which point he is switched to the salvage regimen s. The four candidate drug regimens are cyclophosphamide, vincristine, and dexamethasone (CVD); ketoconazole plus doxorubicin alternating with vinblastine plus estramustine (KA/VE); paclitaxel, estramustine, and carboplatin (TEC); and paclitaxel, estramustine, and etoposide (TEE). The data used in this analysis were obtained directly from Thall et al. (1).